CClinicalTrials.gg
CompletedNCT03447366EVALDMUpdated Jun 10, 2026

Mitral Doppler as a Predictor of Respiratory Worsening After Vascular Filling

An interventional study of mitral doppler in Respiration, Artificial, Vascular Filling and Echocardiography, sponsored by Centre Hospitalier Metropole Savoie. Completed at 3 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-10.

Sponsored by Centre Hospitalier Metropole Savoie · Not applicable, Interventional, and Diagnostic

Phase
Not applicable
Study type
Interventional
Enrollment
87
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Interventional study of the accuracy of a non-invasive testing by echocardiography to predict respiratory worsening after vascular filling.

Read the detailed description

Mitral Doppler will be performed before vascular filling. Patients will be classified in two groups (normal or high cardiac filling pressure).

The evolution of the respiratory data (SpO2/FiO2) of the two groups of the patients before and after vascular filling will be compared.

02

Conditions studied

  • Respiration, Artificial
  • Vascular Filling
  • Echocardiography
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Mechanical ventilation
  • And hemodynamic failure
  • And decision of the attending physician to perform a vascular filling

Exclusion criteria

Exclusion Criteria:

  • Pregnancy and breast-feeding women
  • Patients deprived of their administrative or judicial freedom
04

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
87 participants (actual)

Study arms

  • Experimental
    Mitral doppler

    Mitral doppler before and after vascular filling

    Diagnostic Test: mitral doppler

Interventions

  • Diagnostic testmitral doppler

    Mitral doppler before and after vascular filling

05

What researchers measure

Primary outcomes

  1. frequency of the occuring of premature degradation respiratory

    definied by a reduction of at least 15% of the SpO2/FiO2 ratio in the 30min following the vascular filling

    Time frame: 30 minutes after vascular filling

06

Study locations

3 sites
  • Ch Bourg En Bresse
    Bourg-en-Bresse, France
  • Centre Hospitalier Metropole Savoie
    Chambéry, 73000, France
  • CHU Grenoble Alpes
    La Tronche, 38700, France
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03447366
Lead sponsor
Centre Hospitalier Metropole Savoie
Responsible party
Sponsor
First posted
Feb 27, 2018
Start date
Jan 30, 2018
Primary completion
Apr 30, 2022
Completion
Apr 30, 2022
Last update
Jun 10, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion